Navigation Links
Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
Date:9/8/2010

LONDON, Sept. 8 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).  EGFR-RP and VEGFR1 have been demonstrated to play key roles in the underlying causes of various cancers including abnormal angiogenesis and uncontrolled cell division.  Similar to vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1 also is implicated in the development and progression of age-related macular degeneration (AMD) and other serious ocular diseases.  The EGFR-RP patent is broadly directed to methods of reducing EGFR-RP with a DNA or RNA molecule, including siRNA molecules.  The sequence covered by the VEGFR1 patent is a potent 25mer siRNA, demonstrating Silence's continued ability to secure meaningful intellectual property protection for its portfolio of 25mer sequences.

"The past several months have seen Silence add a number of high-value patents to its broad RNAi intellectual property portfolio.  Whereas many of these recent issuances have focused on the structural modification of RNAi therapeutics to improve efficacy, today's announcement underscores our efforts to concurrently build critical protection in the equally important areas of siRNA sequences and siRNA delivery," said Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We are particularly pleased that we have been able to secure an additional patent covering 25mer siRNA sequences, validating our belief that we can build a portfolio of proprietary 25mer siRNA sequences that will provide us an added level of protection in the RNAi space.  Furthermore, the breadth of the issued EGFR-RP pa
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
2. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Silence Therapeutics Announces Board Changes
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
7. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
8. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
9. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
10. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
11. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced the appointment ... Warburg Pincus LLC, to the Amgen Board of Directors. ... and the deep, global experience he brings in the ... Bradway , chairman and chief executive officer of Amgen. "Fred,s breadth ... well." Mr. Hassan has been Partner and Managing ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... At Day 3 And All Subsequent Study Visits - ... Sumitomo Pharma Co., Ltd., (DSP) announced today that positive results ... treatment of patients with schizophrenia have been published in ... multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated ...
... VRUS ) announces management will present at the ... Both conferences will be held in New York, NY. , ... will provide an overview of the company at the Goldman ... 3:10 PM (ET) and at the Needham Conference on Thursday ...
Cached Medicine Technology:Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences 2Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences 3
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
(Date:7/31/2015)... ... 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the ... released this new applicator in the United States as an upgrade to the CoolSmooth ... The original applicator required a 2 hour treatment time. The new CoolSmooth Pro ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... M3 USA ... excited to launch three new Board Exam Courses. , The additions of Gastroenterology, ... Board Exam Prep from MDLinx makes preparing for the exam easy and painless. ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... live lecture on pharmaceutical negligence is now available online at ( http://www.lawline.com/cle/course/its-a-wonderful-life-if-you-receive-the-right-meds-a-discussion-of-pharmaceutical-negligence ... with a 94% approval rating from the nationwide audience. The course ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... Hope IVF , is in pursuit of a visionary image that goes beyond the ... the UAE, New Hope IVF has reached extraordinary heights with dependable patient support, affordable ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3
... Israel, Nov. 29 Elbit Imaging Ltd.,(TASE, Nasdaq: ... November,28, 2007, InSightec Ltd. ("InSightec"), a subsidiary of ... an agreement for an internal,round of financing in ... existing,investors, namely: Elbit Ultrasound (Netherlands) B.V., a fully ...
... Satellite Newsfeed Notification ... Friday, 11/30, WASHINGTON, Nov. 29 , ... more than 19,million Americans. Despite its prevalence, depression ... is a,first-of-its-kind study examining the statistical relationship between ...
... benefit for the female hormone , THURSDAY, Nov. 29 ... which is often given with estrogen in hormone replacement ... U.S. researchers say. , They conducted tests on female ... come to this conclusion. , Treatment with estrogen blocked ...
... Week to Experience the, World,s Most Advanced Laparoscopic Surgery ... ... Congress, CLEVELAND, Ohio, November 29 Simbionix unveiled the,latest module ... Global Congress of Minimally Invasive Gynecology., The LAP Mentor(TM) multidisciplinary ...
... Utah, Nov. 29 Nutraceutical,International Corporation (Nasdaq: NUTR ... and year ended September 30, 2007., Net sales ... to $35.7 million for the same quarter of fiscal ... or $0.23 diluted earnings per,share, compared to net income ...
... 29 InSightec Ltd. today,reported that it has closed ... existing investors: Elbit Imaging Ltd. (Nasdaq: EMITF ), ... Company,(NYSE: GE ), MediTech Advisors LLC ("MTA"), a ... managers of the company., The investment will take ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 2Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 3Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 4Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 2Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 3Health News:Progesterone Won't Shield Women Against Alzheimer's 2Health News:Gynecologists Get First Hands-On Experience With Simbionix LAP Mentor(TM) 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 3Health News:Nutraceutical Reports 2007 Fiscal Year End Results 4Health News:Nutraceutical Reports 2007 Fiscal Year End Results 5Health News:Nutraceutical Reports 2007 Fiscal Year End Results 6Health News:InSightec Ltd. Announces US$30 Million Investment Round 2Health News:InSightec Ltd. Announces US$30 Million Investment Round 3
... Injectable Drugs is a dynamic new ... and easy to check on the ... the selected drugs, clear compatibility and ... can quickly take clinical action based ...
... Keep up with the latest in scientific ... market intelligence and knowledge resources from CenterWatch. ... to help you monitor and stay abreast ... medicine: Drugs in Clinical Trials, Clinical Trial ...
... Drug Guide for Nurses with Integrated Calculators, ... Co) is a remarkable advance in drug ... the Davis s Drug Guide (9th Edition) ... weight based medications. This product merges many ...
Make better prescribing decisions with this drug interaction analyzer containing over 3,000 brand names with generic equivalents....
Medicine Products: